In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novozymes AS

Division of Repligen Corp.
www.novozymes.com

Latest From Novozymes AS

Asia Executives To Watch: Takeda China GM; Wuxi NextCODE; Sosei

Takeda hires former Pfizer China executive as its new China GM; Wuxi NextCODE appoints its second COO in six months; Sosei appoints two VPs.

Appointments China

Biodiversity Law Reform Spurs Innovation, But Patent Backlog Remains

Brazil's new biodiversity research law is viewed as a step toward fostering biological innovation, but patent backlogs of 14 years still prove to be a major deterrent to conducting R&D in the country.

Intellectual Property Research & Development

BioNotebook: One deal ends for Vanda, Novartis; five new agreements begin

Vanda, Novartis settle Fanapt dispute; Genentech, Phylogica partner on antibiotics; Janssen licenses Sevion antibody platform; Pfizer accesses Philogen antibodies; Tiziana licenses Novimmune asset; and EpiVax applies Novozymes technology.

Gastrointestinal Neurology

White House: Innovation lures investment to US, but inversion's the devil

The wind is at America's back when it comes to attracting business investment to its shores – with data from AT Kearney's 2013 FDI Confidence Index showing the nation has surged past China, Brazil and India to become the country with the top foreign direct investment (FDI) prospects globally – marking the first time the US has held that spot since 2001, the White House pointed out on 20 May.

United States
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • Repligen Corp.
  • RepliGen Corp.
  • Senior Management
  • Steen Riisgaard, Pres. & CEO
    Lars Green, EVP, CFO
    Per Falholt, EVP, CSO
  • Contact Info
  • Novozymes AS
    Phone: (45) 44 46 00 00
    Krogshoejvej 36
    Bagsvaerd, DK-2880
    Denmark
Advertisement
Advertisement
UsernamePublicRestriction

Register